fenofibrate has been researched along with Blood Pressure, High in 56 studies
Pharmavit: a polyvitamin product, comprising vitamins A, D2, B1, B2, B6, C, E, nicotinamide, & calcium pantothene; may be a promising agent for application to human populations exposed to carcinogenic and genetic hazards of ionizing radiation; RN from CHEMLINE
| Excerpt | Relevance | Reference |
|---|---|---|
| "The combination of antihypertensive agents with micronized fenofibrate can effectively prevent the progression of carotid atherosclerosis and reduce the incidence of stroke in patients with essential hypertension." | 9.12 | Inhibitory effects of micronized fenofibrate on carotid atherosclerosis in patients with essential hypertension. ( Meng, QH; Su, G; Zhu, S, 2006) |
| "Improvement in lipid profiles with fenofibrate in patients with type 2 diabetes was associated with reduced progression from normal albumin excretion to microalbuminuria." | 9.11 | Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS). ( Ansquer, JC; Foucher, C; Rattier, S; Steiner, G; Taskinen, MR, 2005) |
| "Our objective was to determine whether fenofibrate modifies the metabolism of nonesterified (free) fatty acids as a component of its triglyceride-lowering action in male patients with the metabolic syndrome." | 9.10 | Free fatty acid metabolism during fenofibrate treatment of the metabolic syndrome. ( Cater, NB; Grundy, SM; Hadizadeh, DR; Meguro, S; Vega, GL, 2003) |
| "These favourable effects of comicronised fenofibrate both on lipid and non lipid parameters, including insulin sensitivity, may confer to this product a particular interest in the treatment of patients with polymetabolic syndrome X." | 9.09 | Effects of comicronised fenofibrate on lipid and insulin sensitivity in patients with polymetabolic syndrome X. ( Blane, G; Idzior-Walus, B; Kawalec, E; Rostworowski, W; Sieradzki, J; Wójcik, J; Zarnecki, A; Zdzienicka, A, 2000) |
| "We report on a 26-year-old male who presented with fenofibrate-induced rhabdomyolysis with chronic renal failure due to nephrotic syndrome." | 7.78 | Fenofibrate-induced rhabdomyolysis in a patient with chronic renal failure due to nephrotic syndrome: a rare case report. ( Begenik, H; Canbaz, ET; Emre, H; Erdur, FM; Erkoc, R; Soyoral, YU, 2012) |
| "To investigate the effect of PPAR alpha activator fenofibrate on left ventricular hypertrophy and myocardium PPAR alpha (peroxisome proliferator-activated receptor-alpha) expression in spontaneously hypertensive rats (SHR)." | 7.74 | [PPAR alpha activator fenofibrate regressed left ventricular hypertrophy and increased myocardium PPAR alpha expression in spontaneously hypertensive rats]. ( Chen, HJ; Chen, JZ; Wang, XX; Yu, M, 2007) |
| " The present study examined the effects of induction of the renal production of 20-HETE with fenofibrate (FF) on the development of angiotensin II (Ang II)-dependent hypertension in C57BL/6J mice." | 7.73 | Fenofibrate prevents the development of angiotensin II-dependent hypertension in mice. ( Bohman, Q; Flasch, A; Roman, RJ; Stec, DE; Taylor, M; Vera, T, 2005) |
| "The PPAR alpha activator fenofibrate prevented development of hypertension, and improved myocardial inflammation and collagen deposition in Ang II-infused rats." | 7.72 | PPAR alpha activator fenofibrate inhibits myocardial inflammation and fibrosis in angiotensin II-infused rats. ( Amiri, F; Benkirane, K; Cohn, JS; Diep, QN; Endemann, D; Schiffrin, EL, 2004) |
| "Fenofibrate prevented the increase in BP in 4-5 week old SHRSP, reduced BP in 25 week old SHRSP, but had no effect on BP in normotensive SD rats." | 5.31 | Fenofibrate lowers blood pressure in two genetic models of hypertension. ( Quest, DW; Shatara, RK; Wilson, TW, 2000) |
| "9%, respectively) and also for dyslipidemia (160 mg daily of fenofibrate plus simvastatin or placebo plus simvastatin) or for systolic blood-pressure control (target, <120 or <140 mm Hg)." | 5.14 | Effects of medical therapies on retinopathy progression in type 2 diabetes. ( Ambrosius, WT; Chew, EY; Cushman, WC; Danis, RP; Davis, MD; Elam, MB; Esser, BA; Fine, LJ; Gangaputra, S; Genuth, S; Gerstein, HC; Ginsberg, HN; Goff, DC; Greven, CM; Hubbard, L; Lovato, JF; Perdue, LH; Schubart, U, 2010) |
| "The combination of antihypertensive agents with micronized fenofibrate can effectively prevent the progression of carotid atherosclerosis and reduce the incidence of stroke in patients with essential hypertension." | 5.12 | Inhibitory effects of micronized fenofibrate on carotid atherosclerosis in patients with essential hypertension. ( Meng, QH; Su, G; Zhu, S, 2006) |
| "Improvement in lipid profiles with fenofibrate in patients with type 2 diabetes was associated with reduced progression from normal albumin excretion to microalbuminuria." | 5.11 | Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS). ( Ansquer, JC; Foucher, C; Rattier, S; Steiner, G; Taskinen, MR, 2005) |
| "A combination of fenofibrate or losartan with anti-hyperuricaemic agents is a good option for the treatment of gout patients with hypertriglyceridaemia and/or hypertension, though the additional hypouricaemic effect may be modest." | 5.10 | Effects of combination treatment using anti-hyperuricaemic agents with fenofibrate and/or losartan on uric acid metabolism. ( Fukuchi, M; Ka, T; Moriwaki, Y; Takahashi, S; Tsutsumi, Z; Yamamoto, T, 2003) |
| "Our objective was to determine whether fenofibrate modifies the metabolism of nonesterified (free) fatty acids as a component of its triglyceride-lowering action in male patients with the metabolic syndrome." | 5.10 | Free fatty acid metabolism during fenofibrate treatment of the metabolic syndrome. ( Cater, NB; Grundy, SM; Hadizadeh, DR; Meguro, S; Vega, GL, 2003) |
| "These favourable effects of comicronised fenofibrate both on lipid and non lipid parameters, including insulin sensitivity, may confer to this product a particular interest in the treatment of patients with polymetabolic syndrome X." | 5.09 | Effects of comicronised fenofibrate on lipid and insulin sensitivity in patients with polymetabolic syndrome X. ( Blane, G; Idzior-Walus, B; Kawalec, E; Rostworowski, W; Sieradzki, J; Wójcik, J; Zarnecki, A; Zdzienicka, A, 2000) |
| "Purpose - studying of clinical efficiensy of the combined therapy (Amlodipin with Valsartan and fibrates) in hypertensive patients with dyslipidemia." | 3.88 | [THE COMBINED THERAPY IN HYPERTENSIVE PATIENTS WITH DYSLIPIDEMIA]. ( Gegeshidze, N; Kapetivadze, V; Lazashvili, T; Maglapheridze, Z; Tabukashvili, R; Tchaava, K, 2018) |
| "We report on a 26-year-old male who presented with fenofibrate-induced rhabdomyolysis with chronic renal failure due to nephrotic syndrome." | 3.78 | Fenofibrate-induced rhabdomyolysis in a patient with chronic renal failure due to nephrotic syndrome: a rare case report. ( Begenik, H; Canbaz, ET; Emre, H; Erdur, FM; Erkoc, R; Soyoral, YU, 2012) |
| " Patients were eligible for the analysis if they had a diagnosis of hypertension, dyslipidaemia or diabetes mellitus, were written a prescription for standard fenofibrate 160 mg during the period 1 May 2004 to 30 April 2005, and were written a subsequent prescription for fenofibrate 145 mg NFE at least 60 days after first receiving the 160 mg dose." | 3.74 | Retrospective comparison of the effectiveness of a fenofibrate 145 mg formulation compared with the standard 160 mg tablet. ( Davidson, MH; Jones, PH, 2008) |
| " We investigated its role in angiotensin II-induced hypertension in the Tsukuba hypertensive mouse (THM)." | 3.74 | Absence of peroxisome proliferator-activated receptor-alpha abolishes hypertension and attenuates atherosclerosis in the Tsukuba hypertensive mouse. ( Bak, S; Coleman, T; Osher, E; Semenkovich, CF; Stern, N; Tordjman, KM; Vechoropoulos, M; Yudovich, R, 2007) |
| "To investigate the effect of PPAR alpha activator fenofibrate on left ventricular hypertrophy and myocardium PPAR alpha (peroxisome proliferator-activated receptor-alpha) expression in spontaneously hypertensive rats (SHR)." | 3.74 | [PPAR alpha activator fenofibrate regressed left ventricular hypertrophy and increased myocardium PPAR alpha expression in spontaneously hypertensive rats]. ( Chen, HJ; Chen, JZ; Wang, XX; Yu, M, 2007) |
| " The present study examined the effects of induction of the renal production of 20-HETE with fenofibrate (FF) on the development of angiotensin II (Ang II)-dependent hypertension in C57BL/6J mice." | 3.73 | Fenofibrate prevents the development of angiotensin II-dependent hypertension in mice. ( Bohman, Q; Flasch, A; Roman, RJ; Stec, DE; Taylor, M; Vera, T, 2005) |
| "Peroxisome proliferator-activated receptor (PPAR) activation may prevent cardiac hypertrophy and inhibit production of endothelin-1 (ET-1), a hypertrophic agent." | 3.72 | Peroxisome proliferator-activated receptor-alpha and receptor-gamma activators prevent cardiac fibrosis in mineralocorticoid-dependent hypertension. ( Amiri, F; Diep, QN; Iglarz, M; Paradis, P; Schiffrin, EL; Touyz, RM; Viel, EC, 2003) |
| "The PPAR alpha activator fenofibrate prevented development of hypertension, and improved myocardial inflammation and collagen deposition in Ang II-infused rats." | 3.72 | PPAR alpha activator fenofibrate inhibits myocardial inflammation and fibrosis in angiotensin II-infused rats. ( Amiri, F; Benkirane, K; Cohn, JS; Diep, QN; Endemann, D; Schiffrin, EL, 2004) |
| "Inducing renal cytochrome P4504A (P4504A) activity with clofibrate prevents the development of hypertension in Dahl salt-sensitive (Dahl S) rats." | 3.70 | Effects of lipid-lowering agents in the Dahl salt-sensitive rat. ( Alonso-Galicia, M; Roman, RJ; Wilson, TW, 1998) |
| " It has been proposed that the elevated serum uric acid levels are linked to other risk factors, such as hypertension, dyslipidaemia and diabetes." | 3.70 | Management of hypertension and dyslipidaemia in patients presenting with hyperuricaemia: case histories. ( Elisaf, MS; Milionis, HJ, 2000) |
| "Patients with the metabolic syndrome are more likely to develop type 2 diabetes and may have an increased risk of cardiovascular disease (CVD) events." | 2.76 | Impact of metabolic syndrome and its components on cardiovascular disease event rates in 4900 patients with type 2 diabetes assigned to placebo in the FIELD randomised trial. ( Colman, PG; Davis, TM; Donoghoe, M; Fulcher, G; Keech, AC; Manning, P; O'Brien, R; Pardy, C; Scott, R; Taskinen, MR; Watts, GF, 2011) |
| "Fenofibrate combined with candesartan improves endothelial function and reduces inflammatory markers to a greater extent than monotherapy in hypertriglyceridemic hypertensive patients." | 2.72 | Additive beneficial effects of fenofibrate combined with candesartan in the treatment of hypertriglyceridemic hypertensive patients. ( Ahn, JY; Chung, WJ; Han, SH; Kim, JA; Koh, KK; Lee, Y; Quon, MJ; Shin, EK, 2006) |
| "Hypertension and hyperlipidemia, which are also responsible for cardiovascular diseases, are often associated with hyperuricemia." | 2.44 | [Other antihyperuricemic agents]. ( Hisatome, I; Igawa, O; Ogino, K, 2008) |
| "Metabolic syndrome is associated with increased cardiovascular risk." | 2.41 | [Fibrate influence on lipids and insulin resistance in patients with metabolic syndrome]. ( Idzior-Waluś, B, 2001) |
| "Fenofibrate has been used for decades against hypercholesterolemia and has no serious side effects." | 1.56 | Fenofibrate increases the amount of sulfatide which seems beneficial against Covid-19. ( Buschard, K, 2020) |
| "Hypertension is associated with endothelial dysfunction, which favors the release of endothelium-derived contracting factors, including vasoconstrictor prostanoids and reactive oxygen species." | 1.48 | PPAR-α agonists acutely inhibit Ca ( Chen, H; Leung, SWS; Man, RYK, 2018) |
| "Fenofibrate was used as the PPARα agonist." | 1.37 | Reactivation of peroxisome proliferator-activated receptor alpha in spontaneously hypertensive rat: age-associated paradoxical effect on the heart. ( Nair, RR; Purushothaman, S; Sathik, MM, 2011) |
| "Fenofibrate prevented the increase in BP in 4-5 week old SHRSP, reduced BP in 25 week old SHRSP, but had no effect on BP in normotensive SD rats." | 1.31 | Fenofibrate lowers blood pressure in two genetic models of hypertension. ( Quest, DW; Shatara, RK; Wilson, TW, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (3.57) | 18.2507 |
| 2000's | 31 (55.36) | 29.6817 |
| 2010's | 21 (37.50) | 24.3611 |
| 2020's | 2 (3.57) | 2.80 |
| Authors | Studies |
|---|---|
| Willson, TM | 1 |
| Brown, PJ | 1 |
| Sternbach, DD | 1 |
| Henke, BR | 1 |
| Teoh, CS | 1 |
| Yuen, YS | 1 |
| Buschard, K | 1 |
| Skolnik, N | 1 |
| Jaffa, FM | 1 |
| Kalyani, RR | 1 |
| Johnson, E | 1 |
| Shubrook, JH | 1 |
| Chen, H | 1 |
| Man, RYK | 1 |
| Leung, SWS | 1 |
| Gremmels, H | 1 |
| Joles, JA | 1 |
| Tabukashvili, R | 1 |
| Kapetivadze, V | 1 |
| Tchaava, K | 1 |
| Gegeshidze, N | 1 |
| Lazashvili, T | 1 |
| Maglapheridze, Z | 1 |
| Zhu, Y | 2 |
| Wang, HS | 1 |
| Li, XM | 1 |
| Qu, C | 3 |
| Weng, H | 1 |
| Ji, X | 1 |
| Endo, K | 1 |
| Iwai, N | 1 |
| Ismael, S | 1 |
| Purushothaman, S | 2 |
| Harikrishnan, VS | 1 |
| Nair, RR | 2 |
| Koh, KK | 3 |
| Quon, MJ | 2 |
| Davidson, MH | 1 |
| Jones, PH | 1 |
| Lai, MY | 1 |
| Lin, CC | 1 |
| Chung, SL | 1 |
| Wu, CH | 1 |
| Yang, WC | 1 |
| Tseng, YT | 1 |
| Hou, X | 1 |
| Shen, YH | 1 |
| Li, C | 1 |
| Wang, F | 1 |
| Zhang, C | 1 |
| Bu, P | 1 |
| Zhang, Y | 1 |
| Nilsson, PM | 1 |
| Chew, EY | 1 |
| Ambrosius, WT | 1 |
| Davis, MD | 1 |
| Danis, RP | 1 |
| Gangaputra, S | 1 |
| Greven, CM | 1 |
| Hubbard, L | 1 |
| Esser, BA | 1 |
| Lovato, JF | 1 |
| Perdue, LH | 1 |
| Goff, DC | 1 |
| Cushman, WC | 1 |
| Ginsberg, HN | 1 |
| Elam, MB | 1 |
| Genuth, S | 1 |
| Gerstein, HC | 1 |
| Schubart, U | 1 |
| Fine, LJ | 1 |
| Ruiz, J | 1 |
| Egli, M | 1 |
| Gianinazzi, F | 1 |
| Izzo, F | 1 |
| Voeffray Favre, AC | 1 |
| Rossi, I | 1 |
| Bodenman, P | 1 |
| Gelosa, P | 1 |
| Banfi, C | 1 |
| Gianella, A | 1 |
| Brioschi, M | 1 |
| Pignieri, A | 1 |
| Nobili, E | 1 |
| Castiglioni, L | 1 |
| Cimino, M | 1 |
| Tremoli, E | 1 |
| Sironi, L | 1 |
| Liew, G | 1 |
| Wang, JJ | 1 |
| Mitchell, P | 1 |
| Siegel, D | 1 |
| Swislocki, AL | 1 |
| Sathik, MM | 1 |
| Erdur, FM | 1 |
| Soyoral, YU | 1 |
| Emre, H | 1 |
| Begenik, H | 1 |
| Canbaz, ET | 1 |
| Erkoc, R | 1 |
| Scott, R | 1 |
| Donoghoe, M | 1 |
| Watts, GF | 1 |
| O'Brien, R | 1 |
| Pardy, C | 1 |
| Taskinen, MR | 2 |
| Davis, TM | 1 |
| Colman, PG | 1 |
| Manning, P | 1 |
| Fulcher, G | 1 |
| Keech, AC | 1 |
| Rehman, HU | 1 |
| Tang, L | 1 |
| Leung, SW | 1 |
| Vanhoutte, PM | 1 |
| Man, RY | 1 |
| Iglarz, M | 2 |
| Touyz, RM | 2 |
| Amiri, F | 3 |
| Lavoie, MF | 1 |
| Diep, QN | 3 |
| Schiffrin, EL | 3 |
| Bardin, T | 1 |
| Takahashi, S | 1 |
| Moriwaki, Y | 1 |
| Yamamoto, T | 1 |
| Tsutsumi, Z | 1 |
| Ka, T | 1 |
| Fukuchi, M | 1 |
| Viel, EC | 1 |
| Paradis, P | 1 |
| Vega, GL | 1 |
| Cater, NB | 1 |
| Hadizadeh, DR | 1 |
| Meguro, S | 1 |
| Grundy, SM | 1 |
| Muller, DN | 1 |
| Theuer, J | 1 |
| Shagdarsuren, E | 1 |
| Kaergel, E | 1 |
| Honeck, H | 1 |
| Park, JK | 1 |
| Markovic, M | 1 |
| Barbosa-Sicard, E | 1 |
| Dechend, R | 1 |
| Wellner, M | 1 |
| Kirsch, T | 1 |
| Fiebeler, A | 1 |
| Rothe, M | 1 |
| Haller, H | 1 |
| Luft, FC | 1 |
| Schunck, WH | 1 |
| Benkirane, K | 1 |
| Cohn, JS | 1 |
| Endemann, D | 1 |
| Ogata, T | 1 |
| Miyauchi, T | 1 |
| Sakai, S | 1 |
| Takanashi, M | 1 |
| Irukayama-Tomobe, Y | 1 |
| Yamaguchi, I | 1 |
| Vera, T | 1 |
| Taylor, M | 1 |
| Bohman, Q | 1 |
| Flasch, A | 1 |
| Roman, RJ | 2 |
| Stec, DE | 1 |
| Ansquer, JC | 1 |
| Foucher, C | 1 |
| Rattier, S | 1 |
| Steiner, G | 1 |
| Coban, E | 1 |
| Ozdogan, M | 1 |
| Yazicioglu, G | 1 |
| Sari, R | 1 |
| Erol, A | 1 |
| Han, SH | 1 |
| Chung, WJ | 1 |
| Ahn, JY | 1 |
| Kim, JA | 1 |
| Lee, Y | 1 |
| Shin, EK | 1 |
| Ichihara, S | 1 |
| Obata, K | 1 |
| Yamada, Y | 1 |
| Nagata, K | 1 |
| Noda, A | 1 |
| Ichihara, G | 1 |
| Yamada, A | 1 |
| Kato, T | 1 |
| Izawa, H | 1 |
| Murohara, T | 1 |
| Yokota, M | 1 |
| Zhu, S | 1 |
| Su, G | 1 |
| Meng, QH | 1 |
| Duhaney, TA | 2 |
| Cui, L | 2 |
| Rude, MK | 1 |
| Lebrasseur, NK | 2 |
| Ngoy, S | 1 |
| De Silva, DS | 2 |
| Siwik, DA | 1 |
| Liao, R | 1 |
| Sam, F | 2 |
| Ip, PC | 1 |
| Joseph, L | 1 |
| Yagil, C | 1 |
| Yagil, Y | 1 |
| Tordjman, KM | 1 |
| Semenkovich, CF | 1 |
| Coleman, T | 1 |
| Yudovich, R | 1 |
| Bak, S | 1 |
| Osher, E | 1 |
| Vechoropoulos, M | 1 |
| Stern, N | 1 |
| Chen, HJ | 1 |
| Chen, JZ | 1 |
| Wang, XX | 1 |
| Yu, M | 1 |
| Carlson, JA | 1 |
| Mazza, J | 1 |
| Kircher, K | 1 |
| Tran, TA | 1 |
| Ogino, K | 1 |
| Igawa, O | 1 |
| Hisatome, I | 1 |
| Wilson, TW | 2 |
| Alonso-Galicia, M | 1 |
| Elisaf, M | 2 |
| Tsimichodimos, V | 1 |
| Bairaktari, E | 2 |
| Siamopoulos, KC | 1 |
| Shatara, RK | 1 |
| Quest, DW | 1 |
| Idzior-Walus, B | 2 |
| Sieradzki, J | 1 |
| Rostworowski, W | 1 |
| Zdzienicka, A | 1 |
| Kawalec, E | 1 |
| Wójcik, J | 1 |
| Zarnecki, A | 1 |
| Blane, G | 1 |
| Milionis, HJ | 1 |
| Elisaf, MS | 1 |
| Achimastos, A | 1 |
| Liberopoulos, E | 1 |
| Nikas, S | 1 |
| Miltiadous, G | 1 |
| Tsimihodimos, V | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Action to Control Cardiovascular Risk in Diabetes (ACCORD)[NCT00000620] | Phase 3 | 10,251 participants (Actual) | Interventional | 1999-09-30 | Completed | ||
| Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study[NCT00542178] | Phase 3 | 3,472 participants (Actual) | Interventional | 2003-10-31 | Completed | ||
| Effects of Fenofibrate Administration in Patients With Diabetic Nephropathy[NCT03869931] | Phase 3 | 300 participants (Anticipated) | Interventional | 2019-03-08 | Recruiting | ||
| Effects of Fenofibrate on Metabolic and Reproductive Parameters in Polycystic Ovary Syndrome. A Randomized, Double-Blind, Placebo-Controlled Trial[NCT00884819] | 4 participants (Actual) | Interventional | 2008-12-31 | Terminated (stopped due to Poor recruitment) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Time to death from any cause. Secondary measure for Glycemia Trial.~A finding of higher mortality in the intensive-therapy group led to an early discontinuation of therapy after a mean of 3.5 years of follow-up. Intensive arm participants were transitioned to standard arm strategy over a period of 0.2 year and followed for an additional 1.2 years to the planned end of the Glycemia Trial while participating in one of the other sub-trials (BP or Lipid)." (NCT00000620)
Timeframe: 4.9 years
| Intervention | participants (Number) |
|---|---|
| Glycemia Trial: Intensive Control | 391 |
| Glycemia Trial: Standard Control | 327 |
"Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. This was the primary outcome measure in all three trials: Glycemia (all participants), Blood Pressure (subgroup of participants not in Lipid Trial), and Lipid (subgroup of participants not in Blood Pressure Trial).~In the Glycemia Trial, a finding of higher mortality in the intensive arm group led to an early discontinuation of therapy after a mean of 3.5 years of follow-up. Intensive arm participants were transitioned to standard arm strategy over a period of 0.2 year and followed for an additional 1.2 years to the planned end of the Glycemia Trial while participating in one of the other sub-trials (BP or Lipid) to their planned completion." (NCT00000620)
Timeframe: 4.9 years
| Intervention | participants (Number) |
|---|---|
| Glycemia Trial: Intensive Control | 503 |
| Glycemia Trial: Standard Control | 543 |
Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. Primary outcome for Blood Pressure Trial. (NCT00000620)
Timeframe: 4.7 years
| Intervention | participants (Number) |
|---|---|
| BP Trial: Intensive Control | 208 |
| BP Trial: Standard Control | 237 |
Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death in Lipid Trial participants. (NCT00000620)
Timeframe: 4.7 years
| Intervention | participants (Number) |
|---|---|
| Lipid Trial: Fenofibrate | 291 |
| Lipid Trial: Placebo | 310 |
Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, cardiovascular death, revascularization procedure or hospitalization for CHF in Lipid Trial participants. (NCT00000620)
Timeframe: 4.7 years
| Intervention | participants (Number) |
|---|---|
| Lipid Trial: Fenofibrate | 641 |
| Lipid Trial: Placebo | 667 |
Time to first occurrence of nonfatal or fatal stroke among participants in the BP Trial. (NCT00000620)
Timeframe: 4.7 years
| Intervention | participants (Number) |
|---|---|
| BP Trial: Intensive Control | 36 |
| BP Trial: Standard Control | 62 |
(NCT00542178)
Timeframe: Measured at Year 4
| Intervention | Participants (Count of Participants) |
|---|---|
| Intensive Glycemia Control | 547 |
| Standard Glycemia Control | 623 |
| Intensive Blood Pressure Control | 266 |
| Standard Blood Pressure Control | 300 |
| Fenofibrate + Simvastatin Therapy | 305 |
| Placebo + Simvastatin Therapy | 299 |
(NCT00542178)
Timeframe: Measured at Year 4
| Intervention | Participants (Count of Participants) |
|---|---|
| Intensive Glycemia Control | 44 |
| Standard Glycemia Control | 40 |
| Intensive Blood Pressure Control | 18 |
| Standard Blood Pressure Control | 20 |
| Fenofibrate + Simvastatin Therapy | 24 |
| Placebo + Simvastatin Therapy | 22 |
(NCT00542178)
Timeframe: Measured at Year 4
| Intervention | Participants (Count of Participants) |
|---|---|
| Intensive Glycemia Control | 744 |
| Standard Glycemia Control | 752 |
| Intensive Blood Pressure Control | 367 |
| Standard Blood Pressure Control | 382 |
| Fenofibrate + Simvastatin Therapy | 354 |
| Placebo + Simvastatin Therapy | 393 |
Diabetic retinopathy status was defined according to the eye with the highest level on the ETDRS Final Severity Scale for Persons, as follows: no diabetic retinopathy, a level of less than 20; mild diabetic retinopathy, a level of 20; moderate nonproliferative diabetic retinopathy (NPDR), a level above 20 but less than 53; severe diabetic retinopathy, a level of 53 but less than 60; and proliferative diabetic retinopathy (PDR), a level of 60 or higher. (NCT00542178)
Timeframe: Measured at Year 4
| Intervention | participants (Number) |
|---|---|
| Intensive Glycemia Control | 104 |
| Standard Glycemia Control | 149 |
| Intensive Blood Pressure Control | 67 |
| Standard Blood Pressure Control | 54 |
| Fenofibrate + Simvastatin Therapy | 52 |
| Placebo + Simvastatin Therapy | 80 |
3 reviews available for fenofibrate and Blood Pressure, High
| Article | Year |
|---|---|
The PPARs: from orphan receptors to drug discovery.
Topics: Animals; Diabetes Mellitus; Drug Design; Humans; Hyperlipidemias; Hypertension; Inflammation; Ligand | 2000 |
[Other antihyperuricemic agents].
Topics: Antihypertensive Agents; Cardiovascular Diseases; Drug Therapy, Combination; Fenofibrate; Gout; Gout | 2008 |
[Fibrate influence on lipids and insulin resistance in patients with metabolic syndrome].
Topics: Cardiovascular Diseases; Clofibrate; Fenofibrate; Hemostasis; Humans; Hyperinsulinism; Hyperlipidemi | 2001 |
9 trials available for fenofibrate and Blood Pressure, High
| Article | Year |
|---|---|
Effects of medical therapies on retinopathy progression in type 2 diabetes.
Topics: Antihypertensive Agents; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabe | 2010 |
Effects of medical therapies on retinopathy progression in type 2 diabetes.
Topics: Antihypertensive Agents; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabe | 2010 |
Effects of medical therapies on retinopathy progression in type 2 diabetes.
Topics: Antihypertensive Agents; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabe | 2010 |
Effects of medical therapies on retinopathy progression in type 2 diabetes.
Topics: Antihypertensive Agents; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabe | 2010 |
The ACCORD Study: the devil is in the details.
Topics: Blood Pressure; Cardiovascular Diseases; Data Interpretation, Statistical; Diabetes Mellitus, Type 2 | 2011 |
Impact of metabolic syndrome and its components on cardiovascular disease event rates in 4900 patients with type 2 diabetes assigned to placebo in the FIELD randomised trial.
Topics: Aged; Australia; Cardiovascular Diseases; Cholesterol, HDL; Cohort Studies; Diabetes Mellitus, Type | 2011 |
Effects of combination treatment using anti-hyperuricaemic agents with fenofibrate and/or losartan on uric acid metabolism.
Topics: Adult; Angiotensin Receptor Antagonists; Drug Therapy, Combination; Fenofibrate; Gout Suppressants; | 2003 |
Free fatty acid metabolism during fenofibrate treatment of the metabolic syndrome.
Topics: Adipose Tissue; Cholesterol; Cholesterol, HDL; Cholesterol, VLDL; Fatty Acids, Nonesterified; Fenofi | 2003 |
Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS).
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Anti | 2005 |
Additive beneficial effects of fenofibrate combined with candesartan in the treatment of hypertriglyceridemic hypertensive patients.
Topics: Adiponectin; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphe | 2006 |
Inhibitory effects of micronized fenofibrate on carotid atherosclerosis in patients with essential hypertension.
Topics: Anti-Inflammatory Agents; Antihypertensive Agents; Biomarkers; Carotid Artery Diseases; Demography; | 2006 |
Effects of comicronised fenofibrate on lipid and insulin sensitivity in patients with polymetabolic syndrome X.
Topics: Adult; Alanine Transaminase; Alkaline Phosphatase; Aspartate Aminotransferases; Blood Glucose; Blood | 2000 |
44 other studies available for fenofibrate and Blood Pressure, High
| Article | Year |
|---|---|
Spectral-Domain OCT Imaging of Lipemia Retinalis.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Diabetes Complications; Drug Therapy, Combinati | 2021 |
Fenofibrate increases the amount of sulfatide which seems beneficial against Covid-19.
Topics: Adult; Aging; Betacoronavirus; Child; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Reducing CV risk in diabetes: An ADA update.
Topics: Antihypertensive Agents; Aspirin; Benzhydryl Compounds; Cardiovascular Diseases; Contraindications; | 2017 |
PPAR-α agonists acutely inhibit Ca
Topics: Animals; Antihypertensive Agents; Antioxidants; Aorta; Disease Models, Animal; Fenofibrate; Hydrogen | 2018 |
Fibrates in hypertension: where do we stand?
Topics: Animals; Fenofibrate; Fibric Acids; Hypertension; Rats; Rats, Inbred SHR; Stroke | 2018 |
[THE COMBINED THERAPY IN HYPERTENSIVE PATIENTS WITH DYSLIPIDEMIA].
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Drug Combinations; Drug Therapy, Combination; Dysl | 2018 |
Effects and mechanisms of Fenofibrate on the secretion of vascular endothelial contraction factors in hypertensive rats.
Topics: Anilides; Animals; Aorta; Cyclooxygenase 1; Dinoprost; Dose-Response Relationship, Drug; Endothelium | 2014 |
Pex11a deficiency is associated with a reduced abundance of functional peroxisomes and aggravated renal interstitial lesions.
Topics: Animals; Disease Models, Animal; Fatty Acids; Female; Fenofibrate; Fibrosis; Hypertension; Hypolipid | 2014 |
Ligand specific variation in cardiac response to stimulation of peroxisome proliferator-activated receptor-alpha in spontaneously hypertensive rat.
Topics: Acyl-CoA Dehydrogenase; Animals; Blood Pressure; Cardiomegaly; Fenofibrate; Gene Expression; Hyperte | 2015 |
Combination therapy for treatment or prevention of atherosclerosis.
Topics: Atherosclerosis; Benzimidazoles; Biphenyl Compounds; Diabetes Mellitus, Type 2; Drug Therapy, Combin | 2008 |
Retrospective comparison of the effectiveness of a fenofibrate 145 mg formulation compared with the standard 160 mg tablet.
Topics: Aged; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus; Dose-Response Relationship | 2008 |
Milky plasma, diabetes, and severe hyponatremia.
Topics: Aged; Diabetes Mellitus, Type 2; Female; Fenofibrate; Humans; Hyperlipidemias; Hypertension; Hyponat | 2009 |
PPARalpha agonist fenofibrate protects the kidney from hypertensive injury in spontaneously hypertensive rats via inhibition of oxidative stress and MAPK activity.
Topics: Animals; Antioxidants; Collagen; Fenofibrate; Hypertension; Kidney Diseases; Male; MAP Kinase Kinase | 2010 |
ACCORD and Risk-Factor Control in Type 2 Diabetes.
Topics: Antihypertensive Agents; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combinati | 2010 |
[Treatments for cardiovascular risk factors and screening for coronary artery disease in type 2 diabetes mellitus].
Topics: Coronary Disease; Diabetes Mellitus, Type 2; Dyslipidemias; Evidence-Based Medicine; Fenofibrate; Hu | 2010 |
Peroxisome proliferator-activated receptor {alpha} agonism prevents renal damage and the oxidative stress and inflammatory processes affecting the brains of stroke-prone rats.
Topics: Animals; Blotting, Western; Brain; Chemokine CCL2; Clofibrate; Disease Models, Animal; Fenofibrate; | 2010 |
Retinopathy progression in type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Diabetic Retinopathy; Disease Progression; Fenofibrate; Humans; Hypertens | 2010 |
Reactivation of peroxisome proliferator-activated receptor alpha in spontaneously hypertensive rat: age-associated paradoxical effect on the heart.
Topics: Aging; Animals; Azo Compounds; Blood Pressure; Body Weight; Cholesterol; Disease Models, Animal; Ene | 2011 |
Fenofibrate-induced rhabdomyolysis in a patient with chronic renal failure due to nephrotic syndrome: a rare case report.
Topics: Adult; Fatigue; Fenofibrate; Humans; Hypertension; Hypoalbuminemia; Hypolipidemic Agents; Kidney Fai | 2012 |
The work-up for mixed hyperlipidemia: a case study.
Topics: Adult; Cholesterol; Cholesterol, HDL; Diabetes Mellitus, Type 2; Electrophoresis; Fenofibrate; Fluor | 2012 |
Effect of fenofibrate on the secretion of endothelium-derived contracting factors in hypertensive rats.
Topics: Animals; Cyclooxygenase 1; Epoprostenol; Fenofibrate; Hypertension; Male; Membrane Proteins; Rats; R | 2012 |
Wy14643 improves vascular function in the aorta of the spontaneously hypertensive rat mainly by activating peroxisome proliferator-activated receptors alpha.
Topics: Animals; Aorta, Thoracic; Fenofibrate; Hypertension; In Vitro Techniques; Male; Peroxisome Prolifera | 2012 |
Does fenofibrate lower blood pressure?
Topics: Antihypertensive Agents; Blood Pressure; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase In | 2013 |
Effect of peroxisome proliferator-activated receptor-alpha and -gamma activators on vascular remodeling in endothelin-dependent hypertension.
Topics: Animals; Blood Pressure; Body Weight; Endothelin-1; Endothelins; Extracellular Matrix; Fenofibrate; | 2003 |
Fenofibrate and losartan.
Topics: Drug Therapy, Combination; Fenofibrate; Gout Suppressants; Humans; Hypertension; Hyperuricemia; Losa | 2003 |
Peroxisome proliferator-activated receptor-alpha and receptor-gamma activators prevent cardiac fibrosis in mineralocorticoid-dependent hypertension.
Topics: Animals; Blood Pressure; Body Weight; Cardiomegaly; Collagen; Desoxycorticosterone; Endothelin-1; En | 2003 |
A peroxisome proliferator-activated receptor-alpha activator induces renal CYP2C23 activity and protects from angiotensin II-induced renal injury.
Topics: 8,11,14-Eicosatrienoic Acid; Angiotensin II; Angiotensinogen; Animals; Animals, Genetically Modified | 2004 |
PPAR alpha activator fenofibrate inhibits myocardial inflammation and fibrosis in angiotensin II-infused rats.
Topics: Angiotensin II; Animals; Blood Pressure; Collagen; Electrocardiography; Fenofibrate; Fibrosis; Heart | 2004 |
Myocardial fibrosis and diastolic dysfunction in deoxycorticosterone acetate-salt hypertensive rats is ameliorated by the peroxisome proliferator-activated receptor-alpha activator fenofibrate, partly by suppressing inflammatory responses associated with
Topics: Animals; Blotting, Western; Cardiac Output, Low; Desoxycorticosterone; Diastole; Fenofibrate; Fibros | 2004 |
Fenofibrate prevents the development of angiotensin II-dependent hypertension in mice.
Topics: Angiotensin II; Animals; Blood Pressure; Cytochrome P-450 CYP4A; Cytochrome P-450 Enzyme System; Fen | 2005 |
The effect of fenofibrate on the levels of high sensitivity C-reactive protein in dyslipidaemic hypertensive patients.
Topics: Adult; Anti-Inflammatory Agents; Body Mass Index; C-Reactive Protein; Fenofibrate; Humans; Hyperlipi | 2005 |
PPARalpha activators may play role for the regression of ventricular hypertrophy in hypertensive and hyperlipidemic patients.
Topics: Clinical Trials as Topic; Evidence-Based Medicine; Fenofibrate; Humans; Hyperlipidemias; Hypertensio | 2006 |
Attenuation of cardiac dysfunction by a PPAR-alpha agonist is associated with down-regulation of redox-regulated transcription factors.
Topics: Animals; Cytokines; Down-Regulation; Fenofibrate; Glucose; Heart Ventricles; Hypertension; Hypertrop | 2006 |
Peroxisome proliferator-activated receptor alpha-independent actions of fenofibrate exacerbates left ventricular dilation and fibrosis in chronic pressure overload.
Topics: Aldosterone; Animals; Cells, Cultured; Chronic Disease; Extracellular Signal-Regulated MAP Kinases; | 2007 |
Effects of fenofibrate on cardiac remodeling in aldosterone-induced hypertension.
Topics: Aldosterone; Animals; Blood Pressure; Extracellular Matrix; Fenofibrate; Fibrosis; Heart; Heart Rate | 2007 |
Peroxisome proliferator-activated receptor alpha: friend or foe?
Topics: Animals; Atherosclerosis; Blood Pressure; Docosahexaenoic Acids; Fenofibrate; Humans; Hypertension; | 2007 |
Absence of peroxisome proliferator-activated receptor-alpha abolishes hypertension and attenuates atherosclerosis in the Tsukuba hypertensive mouse.
Topics: Aldosterone; Angiotensin II; Animals; Atherosclerosis; Blood Pressure; Cardiomegaly; Diet, Atherogen | 2007 |
[PPAR alpha activator fenofibrate regressed left ventricular hypertrophy and increased myocardium PPAR alpha expression in spontaneously hypertensive rats].
Topics: Animals; Blood Pressure; Blotting, Western; Fenofibrate; Hypertension; Hypertrophy, Left Ventricular | 2007 |
Otophyma: a case report and review of the literature of lymphedema (elephantiasis) of the ear.
Topics: Adrenal Cortex Hormones; Alcoholism; Anti-Infective Agents; Anti-Inflammatory Agents; Antidepressive | 2008 |
Effects of lipid-lowering agents in the Dahl salt-sensitive rat.
Topics: Animals; Blood Pressure; Cholesterol; Clofibrate; Cytochrome P-450 CYP4A; Cytochrome P-450 Enzyme Sy | 1998 |
Effect of micronized fenofibrate and losartan combination on uric acid metabolism in hypertensive patients with hyperuricemia.
Topics: Adult; Aged; Antihypertensive Agents; Blood Chemical Analysis; Female; Fenofibrate; Humans; Hyperten | 1999 |
Fenofibrate lowers blood pressure in two genetic models of hypertension.
Topics: Animals; Blood Glucose; Blood Pressure; Fenofibrate; Hypertension; Hypolipidemic Agents; Male; Prote | 2000 |
Management of hypertension and dyslipidaemia in patients presenting with hyperuricaemia: case histories.
Topics: Antihypertensive Agents; Arteriosclerosis; Benzothiadiazines; Diuretics; Female; Fenofibrate; Humans | 2000 |
The effects of the addition of micronised fenofibrate on uric acid metabolism in patients receiving indapamide.
Topics: Adult; Aged; Antihypertensive Agents; Apolipoproteins B; Cholesterol; Cholesterol, LDL; Drug Therapy | 2002 |